10
Phase 2–4 trials
MASH / liver disease · Live ClinicalTrials.gov data
Resmetirom (Rezdiffra) clinical trial pipeline
ClinicalTrials.gov lists 10 phase 2–4 trials for resmetirom, 3 of them actively recruiting. The next phase 3 primary completion among them is expected Dec 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.
4
Phase 3 trials
3
Actively recruiting
Dec 2026
Next phase 3 primary completion
5,523
Participants across trials
Madrigal Pharmaceuticals, Inc.
Lead sponsor by trial count
resmetirom (10)7 active2016–2030
resmetirom
'16
'18
'20
'22
'24
'26
'28
'30
resmetirom
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)P2
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)P2
MAESTRO-NASHP3
MAESTRO-NAFLD1P3
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)P3
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)P3
REZMASHP4
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHP2
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIVP2
NOURISH-MASHP4
Upcoming readouts
7 ahead · resmetirom
Select a trial to load its full ClinicalTrials.gov record.
Key resmetirom trials
Top 10 of the 10 registered phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07249788 | REZMASH — Resmiterom Efficacy & Safety in Patients With MASH | Phase 4 | Recruiting | Oct 2026 |
| NCT07680478 | NOURISH-MASH — Nutrition Intervention Combined With Resmetirom for MASH | Phase 4 | Not yet recruiting | Feb 2028 |
| NCT05500222 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NA… | Phase 3 | Active, not recruiting | Dec 2026 |
| NCT04951219 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatt… | Phase 3 | Active, not recruiting | Mar 2027 |
| NCT03900429 | MAESTRO-NASH — A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosi… | Phase 3 | Active, not recruiting | Jan 2028 |
| NCT04197479 | MAESTRO-NAFLD1 — A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Diseas… | Phase 3 | Completed | Jan 2023 |
| NCT07143968 | A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV | Phase 2 | Recruiting | Oct 2027 |
| NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Phase 2 | Recruiting | Aug 2028 |
| NCT02912260 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Oct 2017 |
| NCT03038022 | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2 | Completed | Jan 2018 |
Related drug pipelines
FAQ
- How many clinical trials are running for resmetirom?
- ClinicalTrials.gov currently lists 10 phase 2–4 resmetirom trials: 4 phase 2, 4 phase 3, and 2 phase 4. 3 are actively recruiting.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare resmetirom against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.